Compounds > fluoxetine

fluoxetine and 2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine

fluoxetine has been researched along with 2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine in 12 studies

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (66.67)29.6817
2010's4 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dormann, SM; Haefeli, WE; Kerpen, CJ; Ketabi-Kiyanvash, N; Martin-Facklam, M; Weiss, J1
Cortizo, L; García, N; Innerárity, A; Labeaga, L; Mosquera, R; Orjales, A; Pumar, MC; Toledo, A1
Bish, G; Brown, AD; Fish, PV; Jonathan Fray, M; Stobie, A; Wakenhut, F; Whitlock, GA1
Bish, G; Fish, PV; Fray, MJ; Stobie, A; Wakenhut, F; Whitlock, GA1
Alfinito, P; Bray, J; Cohn, ST; Deecher, DC; Fensome, A; Johnston, G; Koury, E; Mahaney, PE; Marella, MA; McComas, CC; Nogle, L; Trybulski, EJ; Vu, AT; Ye, F; Zhang, P1
Bray, J; Deecher, D; Johnston, G; Koury, E; Mahaney, PE; McComas, CC; Terefenko, EA; Trybulski, E; Vu, A; Zhang, P1
Bray, JA; Cohn, ST; Deecher, DC; Dooley, R; Goljer, I; Johnston, GH; Leiter, J; Mahaney, PE; Moore, WJ; Terefenko, EA; Trybulski, EJ; Vu, AT; Zhang, P1
Bray, J; Deecher, D; Fensome, A; Harrison, J; Kim, C; Koury, E; Mahaney, PE; Mark, L; McComas, CC; Mugford, CA; Terefenko, EA; Trybulski, EJ; Vu, AT; Whiteside, GT; Zhang, P1
Bray, JA; Cohn, ST; Cosmi, SA; Deecher, DC; Harrison, JE; Johnston, GH; Kennedy, JD; Kim, CY; Koury, EJ; Leventhal, L; Mahaney, PE; Smith, VA; Trybulski, EJ; Vu, AT; Whiteside, GT; Zhang, P1
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC1
Ali, S; Dutta, A; Gopishetty, B; Hazeldine, S; Johnson, M; Modi, G; Reith, M; Santra, S; Zhen, J1
Antonio, T; Debnath, J; Dutta, A; Reith, M; Santra, S; Sharma, H1

Other Studies

12 other study(ies) available for fluoxetine and 2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine

ArticleYear
Inhibition of P-glycoprotein by newer antidepressants.
    The Journal of pharmacology and experimental therapeutics, 2003, Volume: 305, Issue:1

    Topics: Animals; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Endothelium, Vascular; Humans; Reproducibility of Results; Swine; Transfection

2003
Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
    Journal of medicinal chemistry, 2003, Dec-04, Volume: 46, Issue:25

    Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Brain; Carrier Proteins; Fluoxetine; In Vitro Techniques; Male; Membrane Glycoproteins; Membrane Transport Proteins; Morpholines; Nerve Tissue Proteins; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Piperidines; Radioligand Assay; Rats; Rats, Wistar; Reboxetine; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Stereoisomerism; Structure-Activity Relationship; Symporters

2003
N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.
    Bioorganic & medicinal chemistry letters, 2006, Aug-15, Volume: 16, Issue:16

    Topics: Amines; Chemistry, Pharmaceutical; Drug Design; Duloxetine Hydrochloride; Humans; Models, Chemical; Norepinephrine; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship; Thiophenes

2006
Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.
    Bioorganic & medicinal chemistry letters, 2006, Aug-15, Volume: 16, Issue:16

    Topics: Amines; Biological Transport; Cell Line; Chemistry, Pharmaceutical; Drug Design; Humans; Inhibitory Concentration 50; Models, Chemical; Piperazine; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship

2006
Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.
    Bioorganic & medicinal chemistry letters, 2008, Sep-15, Volume: 18, Issue:18

    Topics: Humans; Indoles; Molecular Structure; Neurotransmitter Uptake Inhibitors; Norepinephrine; Stereoisomerism; Structure-Activity Relationship

2008
Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors.
    Bioorganic & medicinal chemistry letters, 2008, Dec-01, Volume: 18, Issue:23

    Topics: Benzimidazoles; Combinatorial Chemistry Techniques; Drug Design; Humans; Molecular Structure; Neurotransmitter Uptake Inhibitors; Norepinephrine; Stereoisomerism

2008
3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.
    Bioorganic & medicinal chemistry letters, 2009, May-01, Volume: 19, Issue:9

    Topics: Adrenergic Uptake Inhibitors; Animals; Chemistry, Pharmaceutical; Dogs; Dopamine Plasma Membrane Transport Proteins; Drug Design; Humans; Inhibitory Concentration 50; Ligands; Models, Chemical; Norepinephrine; Propanolamines; Selective Serotonin Reuptake Inhibitors; Structure-Activity Relationship

2009
1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.
    Journal of medicinal chemistry, 2009, Sep-24, Volume: 52, Issue:18

    Topics: Administration, Oral; Animals; Behavior, Animal; Benzimidazoles; Biological Transport; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Hyperalgesia; Male; Neurotransmitter Uptake Inhibitors; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Propanolamines; Rats; Rats, Sprague-Dawley; Serotonin Plasma Membrane Transport Proteins; Spinal Nerves; Structure-Activity Relationship; Substrate Specificity

2009
1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.
    Journal of medicinal chemistry, 2010, Mar-11, Volume: 53, Issue:5

    Topics: Animals; Body Temperature Regulation; Female; Indoles; Magnetic Resonance Spectroscopy; Neurotransmitter Uptake Inhibitors; Norepinephrine Plasma Membrane Transport Proteins; Pain; Propanolamines; Rats; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship

2010
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
    Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24

    Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility

2010
Further structure-activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents.
    Journal of medicinal chemistry, 2011, Apr-28, Volume: 54, Issue:8

    Topics: Animals; Antidepressive Agents; Brain; Magnetic Resonance Spectroscopy; Neurotransmitter Uptake Inhibitors; Pyrans; Rats; Structure-Activity Relationship

2011
Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model.
    Bioorganic & medicinal chemistry, 2014, Jan-01, Volume: 22, Issue:1

    Topics: Antidepressive Agents; Biomimetics; Brain; Computational Biology; Depression; Membrane Transport Proteins; Molecular Conformation; Neurotransmitter Uptake Inhibitors; Pyrans; Stereoisomerism; Structure-Activity Relationship

2014